MaxCyte, Inc. Signing of Strategic Platform License (2190F)
July 06 2023 - 8:05AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2190F
MaxCyte, Inc.
06 July 2023
MaxCyte Signs Strategic Platform License with Lyell
Immunopharma
Lyell Immunopharma to use MaxCyte's Flow Electroporation(R)
technology and ExPERT(TM) platform in its T cell product candidates
targeting solid tumors.
ROCKVILLE, MD, July 06, 2023 - MaxCyte, Inc. , ( Nasdaq: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and to support innovative, cell-based research, today
announced the signing of a strategic platform license (SPL) with
Lyell Immunopharma, Inc., a clinical stage T cell reprogramming
company.
Under the terms of the agreement, Lyell Immunopharma obtains
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is eligible to receive platform licensing fees, clinical
milestone payments and sales-based payments.
"At MaxCyte, our goal is to maximize the potential of cells to
improve patients' lives, and it is through collaborations such as
this that we can achieve success," said Doug Doerfler, President
and CEO of MaxCyte. "We look forward to supporting Lyell
Immunopharma in its development of solid tumor treatments for
patients with unmet needs."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Each of MaxCyte's strategic partnerships
generates pre-commercial milestone revenue and the vast majority
include sales-based payments.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCRFMMTMTJMBLJ
(END) Dow Jones Newswires
July 06, 2023 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024